Development of novel therapy for kidney injury by leukocyte targeting antibody-fused Bionanocapsules

2014 Fiscal Year Final Research Report

• Project/Area Number: 25670408
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Kidney internal medicine
• Research Institution: Nagoya University
• Principal Investigator: MATSUO Seiichi 名古屋大学, 医学(系)研究科(研究院), 教授 (70190410)
• Co-Investigator(Kenkyū-buntansha): TSUBOI Naotake 名古屋大学, 医学部附属病院, 講師 (50566958)
• Co-Investigator(Renkei-kenkyūsha): KURODA Shunichi 名古屋大学, 生命農学研究科, 教授 (60263406)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: マクロファージ / バイオナノカプセル / 腎虚血再灌流障害 / ドラッグデリバリー

Outline of Final Research Achievements

In this study, we aimed the development of evolutional therapy to reconcile both anti-inflammatory/immune suppressive effects and extenuate adverse effects. We applied bionanocapsule-based drug delivery system (DDS) to inhibit immune activation specific for macrophages and selectively at inflammatory sites. We generated fluorescent-conjugated BNC fused with antibody targeting macrophages, and confirmed the BNC distribution on mouse macrophage cell line. Intravenous administration of the BNC into mouse demonstrated fluorescent cells only on injured kidney indicating specific BNC delivery for inflammatory sites. Significant expression of gene enclosed in BNC was not demonstrated, but this study provided fundamental data for the development for leukocyte specific DDS using BNC.

Free Research Field

腎臓学、免疫学